Dear all,Back to the Top
I'm working on a acidic drug that is probably secreted by the kidney
(renal clearance is grater than the glomerular filtration rate in man). As
this drug will be administered to polymedicated patients, it is important to know whether it interacts with other drug known to be actively secreted.
I'm proposing two different study designs:
The first is to conduct a 2 period cross-over study with administration
of the drug alone ( period 1) or concomitant administration of probenecid (a
potent inhibitor of renal secretion)with the drug under investigation( period
The second is to conduct a drug-drug interaction study, using drugs
known to be actively secreted by the kidney and susceptibe to be used in patients such as furosemid, cephalosporins..
What would be more relevant for a drug, confirming that it is secreted
by the kidney ( first design) or assessing potential drug-drug interaction
(second design)? Please provide me with your opinion.
Dear Dr Ezzine,Back to the Top
The above article in BJCP could be interested for your problem.
S. Gross, A. J. McLachlan, I. Minns, J. B. Beal, S. E. Tett
Simultaneous administration of a cocktail of markers to measure renal
drug elimination pathways:
absence of a pharmacokinetic interaction between fluconazole and
sinistrin, p-aminohippuric acid and pindolol.
Kazimierz H. Kozlowski
Laboratory of Pharmacokinetics
The Childrens Memorial Health Institute
04-736 Warsaw, Poland
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (email@example.com)